Erector Spinae Block Versus Thoracic Paravertebral Block for Acute Thoracic Herpes Zoster
Acute Thoracic Herpes Zoster, Erector Spinae Plane Block, Thoracic Paravertebral Block
About this trial
This is an interventional treatment trial for Acute Thoracic Herpes Zoster
Eligibility Criteria
Inclusion Criteria:
- Over 50 years of age
- Chest wall herpetic eruption of less than one week
- Moderate or severe pain
Exclusion Criteria:
- Patient refusal
- Eruption more than one week duration
- Patients who will not receive appropriate anti-viral therapy
- Patients with mild pain
- Infection at the site of injection
- Patients with a history of renal, hepatic diseases, coagulopathy, steroid therapy, malignancies.
- Patient taking chemotherapy and/or radiotherapy.
Sites / Locations
- Tanta University HospitalsRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Control Group
Erector Spinae Block (ESB) group
Thoracic Paravertebral Block group
Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed.
Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography. The concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
Patients will receive 25 mg bupivacaine 0.5%, plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at the desired level under ultrasonography